Journal Article

Geroprotectors: A role in the treatment of frailty


The proportion of the population over the age of 65 is growing the most rapidly due to the longevity revolution. Frailty is prevalent in this age group and strongly associated with disability and hospitalization, having a significant impact on the costs of health and social care. New effective interventions to delay or reverse frailty are urgently required. Geroprotectors are a new class of drugs, which target fundamental mechanisms of ageing and show promise in delaying the onset of or boosting resilience in frail older people. However, there are challenges to their clinical translation. Here we review the literature for evidence that frailty can be delayed or reversed and geroprotectors can improve frailty in murine models and in patients. We will then discuss the challenges, which make their clinical testing complex and propose potential options for moving forward.

Attached files


Trendelenburg, A.U.
Scheuren, A.C.
Potter, P.
Müller, R.
Bellantuono, I.

Oxford Brookes departments

Department of Biological and Medical Sciences


Year of publication: 2019
Date of RADAR deposit: 2019-10-15

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License

Related resources

This RADAR resource is Identical to Geroprotectors: A role in the treatment of frailty


  • Owner: Joseph Ripp
  • Collection: Outputs
  • Version: 1 (show all)
  • Status: Live
  • Views (since Sept 2022): 329